Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

'We Are Going To See More Pain': Standard Chartered Cuts 2026 Bitcoin Forecast From $150K To $100K

View original at finance.yahoo.com
'We Are Going To See More Pain': Standard Chartered Cuts 2026 Bitcoin Forecast From $150K To $100K Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Slim chances of a rate cut until Kevin Warsh potentially takes office in May

    80% confidence
  • Recent cryptocurrency downturn has not led to collapse of any cryptocurrency project or company

    80% confidence
  • Ethereum could fall to $1,400 before rebounding to year-end targets

    80% confidence
  • Long-term drivers for cryptocurrency remain intact despite recent downturn

    80% confidence
  • Bitcoin will fall to $50,000 or below in the short term before rebounding

    80% confidence
  • Bitcoin ETF inflows unlikely to resume until Kevin Warsh potentially takes office in May

    80% confidence
  • Further capitulation in Bitcoin ETFs is likely as investors sit on significant losses with average purchase price of $90,000

    80% confidence
  • Current macroeconomic conditions are unfavorable for cryptocurrency

    80% confidence
  • We are going to see more pain in cryptocurrency markets

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com